Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study

In a study of older men with advanced prostate cancer in Ontario, Canada, researchers found that the type of doctor initially prescribing hormone therapy significantly influenced whether patients received additional, life-extending treatments. Older patients were also less likely to receive these intensified treatments, even when medically appropriate.

Several authors disclosed receiving personal fees, research funding, grants, and/or holding advisory board positions for various pharmaceutical companies, including those manufacturing treatments for prostate cancer (e.g., Janssen, Bayer, Astellas, Merck, Pfizer). These potential conflicts should be considered when interpreting the findings.

This is a well-conducted population-based study that identifies important variations and potential disparities in prostate cancer care. The large sample size and use of real-world data are strengths, but limitations regarding data granularity and generalizability to younger patients prevent a higher rating.